Currently Available Treatment Options for Patients With R/R DLBCL

Video

Drs Loretta J. Nastoupil and Marc S Hoffman explain the available treatment options for relapsed/refractory diffuse large B-cell lymphoma and what to consider when selecting a therapy in the second-line setting.

Related Videos
Sundar Jagannath, MBBS
Krina K. Patel, MD, MSc
Angela Jia, MD, PhD, of University Hospitals
Robert Wang, MD, of Fox Chase Cancer Center
Alexander Kutikov, MD, FACS, of Fox Chase Cancer Center
Roger Li, MD, of Moffitt Cancer Center
Joshua J. Meeks, MD, PhD, of Northwestern University Feinberg School of Medicine
Neal Shore, MD, FACS, of GenesisCare USA and Carolina Urologic Research Center
Mark D. Tyson, II, MD, MPH
Related Content
Gulrayz Ahmed, MD, the Medical College of Wisconsin

Retrospective Analysis Shows Efficacy and Safety of CAR T-Cell Therapy in MCL With SCNS

May 14th 2024
Article
Matthew Lunning, DO, FACP

Lunning and Mehta-Shah Unpack Treatment Needs and Future Directions in PTCL

December 21st 2023
Podcast
Oluwaseun Orikogbo, MD

Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist

May 6th 2024
Article
Matthew Lunning, DO, FACP

Lunning and Nastoupil Highlight Treatment Considerations and Ongoing Research in Follicular Lymphoma

October 30th 2023
Podcast
Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC

Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC

May 6th 2024
Article
Antoni Vilaseca Cabo, MD, of Hospital Clínic de Barcelona

TAR-210 Demonstrates Preliminary Efficacy in FGFR-Altered Non–Muscle-Invasive Bladder Cancer

May 5th 2024
Article